Genitourinary Cancer | Norton Healthcare

Indication: Genitourinary Cancer

An open-label multi-cohort Phase 1b/2 study of derazantinib and atezolizumab in patients with urothelial cancer expressing activating molecular FGFR aberrations (FIDES-02)

Bladder Cancer

Line of Therapy: First or Second Line depending on substudy

Drug Study

Principal Investigator: Jaspreet Grewal, M.D.
Norton Cancer Institute

Sponsor: Basilea Pharmaceutica International Ltd

Learn more at

Email for more information:

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.